Submit Manuscript  

Article Details

New and Old Monoclonal Antibodies for the Treatment of Chronic Lymphocytic Leukemia

[ Vol. 11 , Issue. 6 ]


L. Laurenti, L. De Padua, G. D'Arena, B. Vannata, I. Innocenti, M. Tarnani, S. Deaglio, S. Sica, D. G. Efremov and G. Leone   Pages 508 - 518 ( 11 )


Over the last few years, several new agents have been under evaluation in preclinical studies and clinical trials, showing promise in treating chronic lymphocytic leukemia (CLL). Among these agents, monoclonal antibodies (mAbs) such as rituximab and alemtuzumab have changed the natural course of the disease. Nowadays there are several new promising monoclonal antibodies under investigation against the CD20, CD23, CD37 and CD40 molecules. Application of newer monoclonal antibodies represents an area of ongoing clinical research in CLL.


CD20, CD23, CD37, CD40, CD52, chronic lymphocytic leukemia, monoclonal antibodies, preclinical, CLL, alemtuzumab, rituximab, mAbs


Hematology Department, Catholic University of ‘Sacred Hearth’, Largo Agostino Gemelli, 00168 Rome, Italy.

Read Full-Text article